This week, Zacks Chief Equity Strategist and Economist John Blank, PhD discusses:

• Top stocks in the Medical sector, a large and diverse area of the economy which includes drug manufacturers as well as medical care and medical product companies. In this webinar, John defines “top” stocks using three screening metrics: market capitalization, number of analysts following the stock, and largest percent change in F1 EPS estimate (the most important element used in assigning a Zacks Rank to stocks).

• Using this framework, John then examines key metrics for these leading names, using Zacks charting to illustrate comparisons of the most relevant trends for these companies. To point out strengths and weaknesses among these stocks, he looks at metrics ranging from Revenue F12M, EPS F12M, and Return on Equity to R&D as % of Sales, and DuPont analysis. John also spends some time discussing the role of the FDA in the pharma industry.

• Because he uses 3 types of screening metrics, John’s review of Medical players includes both large and relatively small companies, and both familiar and less well-known names. Among the tickers he discusses are Eli Lilly (LLY), UnitedHealth Group (UNH), Soligenix (SNGX), GoodRx Holdings (GDRX), Astrana Health (ASTH), Progyny (PGNY), and many others. Don’t miss this in-depth analysis from Zacks’ Chief Equity Strategist!